Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

1. Trifan, A., Gheorge, C., Dumitraşcu, D., Diculescu, M., Gheorghe, L., Sporea, I., Ciurea, T. (2018). Gastroenterologie iş Hepatologie Clinicã. Bucharest: Editura Medicalã. Search in Google Scholar

2. Barb, D., Repetto, E. M., Stokes, M. E., Shankar, S. S., & Cusi, K. (2021). Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic liver disease. Obesity: The Journal of the Obesity Society, 11. doi:10.1002/oby.2326310.1002/oby.2326334553836 Search in Google Scholar

3. Clark, J. M., & Diehl, A. M. (2003). Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis. The Journal of the American Medical Association. doi:10.1001/jama.289.22.300010.1001/jama.289.22.300012799409 Search in Google Scholar

4. Onzi, G., Moretti, F., Balbinot, S. S., Balbinot, R. A., & Soldera, J. (2019). Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis. (G.-W. Cao, Ed.) Hepatoma Research. doi:10.20517/2394-5079.2018.11410.20517/2394-5079.2018.114 Search in Google Scholar

5. Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Bonino, F. (2016). Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences. doi:10.3390/ijms1712208210.3390/ijms17122082518788227973438 Search in Google Scholar

6. Severson, T. J., Besur, S., & Bonkovsky, H. L. (2016). Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World Journal of Gastroenterology(22(29)), 6742-6756. doi:10.3748/wjg.v22.i29.674210.3748/wjg.v22.i29.6742497047927547017 Search in Google Scholar

7. Poianã, C., & Fica, S. (2015). Endocrinologie pentru studenţi şi rezidenţi. Bucharest: Editura Universitara „Carol Davila” Bucure?ti. Search in Google Scholar

8. Lujan, P. V., Esmel, E. V., & Meseguer, E. S. (2021). Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. MDPI(13(5)). doi:https://doi.org/10.3390/nu1305144210.3390/nu13051442814587733923255 Search in Google Scholar

9. Rada, P., Gonzalez-Rodrigues, A., Carmelo, G.-M., & Valverde, A. M. (2020). Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver. Cell Death and Disease. doi:https://doi.org/10.1038/s41419-020-03003-w10.1038/s41419-020-03003-w751968532978374 Search in Google Scholar

10. Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic. Biol. Med. 152, 116-141 (2020) Search in Google Scholar

11. Ibrahim, S. H., Kohli, R. & Gores, G. J. Mechanisms of lipotoxicity in NAFLD and clinical implications. J. Pediatr. Gastroenterol. Nutr. 53, 131-140 (2011) Search in Google Scholar

12. Hirsova, P. et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 150, 956-967 (2016)10.1053/j.gastro.2015.12.037480846426764184 Search in Google Scholar

13. Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Invest 127, 55-64 (2017).10.1172/JCI88881519969828045404 Search in Google Scholar

14. Arrese, M., Cabrera, D., Kalergis, A. M. & Feldstein, A. E. Innate immunity and inflammation in NAFLD/NASH. Dig. Dis. Sci. 61, 1294-1303 (2016) Search in Google Scholar

15. Pardo, V., Gonzalez-Rodriguez, A., Guijas, C., Balsinde, J. & Valverde, A. M. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J. Biol. Chem. 290, 11663-11677 (2015) Search in Google Scholar

16. Kazankov, K. et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature reviews. GNat. Rev. Gastroenterol. Hepatol. 16, 145-159 (2019). Search in Google Scholar

17. Chu, X. et al. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. J. Transl. Med. 16, 108 (2018)10.1186/s12967-018-1490-y593782029690903 Search in Google Scholar

18. Li, B. H., He, F. P., Yang, X., Chen, Y. W. & Fan, J. G. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl. Res. 180, 103-117 (2017). Search in Google Scholar

19. Tsuchida, T., and Friedman, S. L. (2017). Mechanisms of Hepatic Stellate Cell Activation. Nat. Rev. Gastroenterol. Hepatol. 14 (7), 397-411. doi:10.1038/nrgastro.2017.3810.1038/nrgastro.2017.3828487545 Search in Google Scholar

20. G. Targher, M. Chonchol, G. Zoppini, C. Abaterusso, and E. Bonora, “Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?” Journal of Hepatology, vol. 54, no. 5, pp. 1020-1029, 2011. Search in Google Scholar

21. J. H. Ix and K. Sharma, “Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK,” Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 406-412, 2010.10.1681/ASN.2009080820447325420150538 Search in Google Scholar

22. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. The incidence and risk factors of hepatocellular carcinoma in Onzi et al. Hepatoma Res 2019;5:7 I http://dx.doi.org/10.20517/2394-5079.2018.114 Page 5 of 7 patients with non-alcoholic steatohepatitis. Hepatology 2010;51:1972-8 Search in Google Scholar

23. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. World J Hepatol 2017;9:533-4310.4254/wjh.v9.i11.533539580228469809 Search in Google Scholar

24. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-70310.1111/apt.14937749549430136293 Search in Google Scholar

25. Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. (2019). Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Liver Disease. Gastroenterology. doi: 10.1053/j.gastro.2018.12.03610.1053/j.gastro.2018.12.036750505230660725 Search in Google Scholar

26. Valeria Annarita Piazzolla, Alessandra Mangia. (2020). Noninvasive Diagnosis of NAFLD and NASH. Cells. doi: 10.3390/cells904100510.3390/cells9041005722647632316690 Search in Google Scholar

27. G. Thomas Brown, David E. Kleiner. (2016). Histopathology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Metabolism. doi: 10.1016/j.metabol.2015.11.00810.1016/j.metabol.2015.11.008488954726775559 Search in Google Scholar

28. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539]10.3748/wjg.v20.i42.15539422951925400438 Search in Google Scholar

29. Arjun J. Sanyal, Elizabeth M. Brunt, David E. Kleiner, Kris Kowdley, Naga Chalasani, Joel Lavine, Vlad Ratziu, Arthur McCullough. (2011). Endpoints and Clinical Trial Design for Nonalcoholic Steatohepatitis. Hepatology. 2011 Jul; 54(1): 344-353. doi: 10.1002/hep.2437610.1002/hep.24376401446021520200 Search in Google Scholar

30. Sweta Tandra, Matthew M. Yeh, Elizabeth M. Brunt, Raj Vuppalanchi, Oscar W. Cummings, Aynur Ünalp-Arida, Laura A. Wilson, Naga Chalasani. Presence and Significance of Microvesicular Steatosis is Nonalcoholic Fatty Liver Disease. Journal of Hepatology. 2011 Sep; 55(3): 654-659. doi: 10.1016/j.jhep.2010.11.02110.1016/j.jhep.2010.11.021313978021172393 Search in Google Scholar

31. G. Celebi, A.F. Cicek, H. Gurel, H. Genc, A.Kirik, C.N. Ercin, T. Dogru. Microvesicular steatosis : a missed item in the management of nonalcoholic fatty liver disease? Acta Gastro-Enterologica Belgica. Oct-Dec 2020;83(4): 565-570. PMID: 33321012 Search in Google Scholar

32. Naga Chalasani, Laura Wilson, David E. Kleiner, Oscar W Cummings, Elizabeth M. Brunt, Aynur Ünalp. (2008). Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2008 May; 48(5): 829-834. doi: 10.1016/j.jhep.2008.01.01610.1016/j.jhep.2008.01.016 Search in Google Scholar

33. Hongfa Zhu, Henry C. Bodenheimer Jr, David J. Chain, Albert D. Min, Neil D. Theise. (2010). Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease. World Journal of Gastroenterology. 2010 Oct 28; 16(40): 5065-5069. doi: 10.3748/wjg.v16.i40.506510.3748/wjg.v16.i40.5065 Search in Google Scholar

34. Elizabeth M. Brunt, David E. Kleiner, Laura A. Wilson, Aynur Ünalp, Cynthia E. Behling, Joel E. Lavine, Brent A. Neushwander-Tetri and the NASH Clinical Research Network. (2009). Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology. 2009 Mar; 49(3): 809-820. doi: 10.1002/hep.2272410.1002/hep.22724 Search in Google Scholar

35. Petra Hirsova, Gregory J. Gores. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology. 2015 Jan; 1(1): 17-27. doi: 10.1016/j.jcmgh.2014.11.00510.1016/j.jcmgh.2014.11.005 Search in Google Scholar

36. Veronika Zámbó, Laura Simon-Szabó, Péter Szelényi, Éva Kereszturi, Gábor Bánhegyi, Miklós Csala. Lipotoxicity in the liver. World Journal of Hepatology. 2013 Oct 27; 5(10): 550-557. doi: 10.4254/wjh. v5.i10.550 Search in Google Scholar

37. Stephen H. Caldwell, Vanessa D. Lee, David E. Kleiner, Abdullah M.S. Al-Osaimi, Curtis K. Argo, Patrick G. Northup, Carl L. Berg. Nash and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology. 2009 Oct-Dec; 8(4): 346-352. PMCID: PMC838124310.1016/S1665-2681(19)31748-X Search in Google Scholar

38. Metin Basaranoglu, Nesrin Turhan, Abdullah Sonsuz, Gökcen Basaranoglu. Mallory-Denk bodies in chronic hepatitis. World Journal of Gastroenterology. 2011 May 7; 17(17): 2172-2177. doi: 10.3748/wjg.v17.i17.217210.3748/wjg.v17.i17.2172309286721633525 Search in Google Scholar

39. Mariana Verdelho Machado, Duarte M. S. Ferreira, Rui E. Castro, Ana Rita Silvestre, Teresinha Evanghelista, João Coutinho, Fátima Carepa, Adília Costa, Cecília M. P. Rodrigues, Helena Cortez-Pinto. Liver and Muscle in Morbid Obesity: The interplay of Fatty Liver and Insulin Resistance. PLoS One. 2012;7(2):e31738. doi: 10.1371/journal.pone.003173810.1371/journal.pone.0031738328100522359625 Search in Google Scholar

40. Gherasim, L. (1999). Medicinã Internã: Vol. III - Bolile digestive, hepatice şi pancreatice. Bucharest: Editura Medicalã Search in Google Scholar

41. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.10.1016/j.jhep.2015.11.00427062661 Search in Google Scholar

42. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risc factors and diagnosis. Expert Rev Gastroenterol Hepatol 2010; 4: 623-35.10.1586/egh.10.5620932147 Search in Google Scholar

43. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.10.1186/1471-230X-6-33163665117081293 Search in Google Scholar

44. Gastaldelli A, Kozakova M, Højlund K, et al. RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-4410.1002/hep.2284519291789 Search in Google Scholar

45. Balkau B, Lange C, Vol S, Fumeron F. Group Study D.E.S.I.R Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.10.1186/1471-230X-10-56289884520529259 Search in Google Scholar

46. Kozakova M, Palombo C, Paterni M, et al. The RISC Investigators. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology 2012; 55: 1406-15.10.1002/hep.2555522334565 Search in Google Scholar

47. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60.10.1111/j.1365-2036.2011.04668.x21517924 Search in Google Scholar

48. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.10.1148/radiol.239105036116484355 Search in Google Scholar

49. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760-1769.10.1136/gut.2006.112094209570717911352 Search in Google Scholar

50. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.10.1016/j.jhep.2008.02.011242346718395287 Search in Google Scholar

51. Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients. 2013;5:2901-2923.10.3390/nu5082901377523423896654 Search in Google Scholar

52. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 2010; 51:121.10.1002/hep.23276279953819827166 Search in Google Scholar

53. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty livers disease: a systematic review and meta-analysis. J Hepatol 2012; 57:157.10.1016/j.jhep.2012.02.02322414768 Search in Google Scholar

54. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149:367.10.1053/j.gastro.2015.04.005 Search in Google Scholar

55. S.E. Keating, J. George, N.A. Johnson. The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol., 9 (2015), pp. 1247-1250. Search in Google Scholar

56. S. Zelber-Sagi, A. Buch, H. Yeshua, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial World J Gastroenterol., 20 (2014), pp. 4382-4392. Search in Google Scholar

57. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.10.1056/NEJMra041001 Search in Google Scholar

58. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-525.10.1111/j.1572-0241.2001.03553.x Search in Google Scholar

59. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-1184.10.1053/j.gastro.2008.06.047 Search in Google Scholar

60. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110.10.1053/j.gastro.2008.03.078 Search in Google Scholar

61. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29:172-182.10.1111/j.1365-2036.2008.03869.x Search in Google Scholar

62. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467.10.1002/hep.510230624 Search in Google Scholar

63. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384.10.1016/S0168-8278(99)80243-8 Search in Google Scholar

64. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490.10.1111/j.1572-0241.2003.08699.x14638353 Search in Google Scholar

65. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419.10.1053/jhep.2003.5031612883485 Search in Google Scholar

66. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006;26:1015-1017.10.1111/j.1478-3231.2006.01315.x16953843 Search in Google Scholar

67. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43:173-181.10.1002/hep.21006292542416374859 Search in Google Scholar

68. Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Bradley Freilich, Muhammad Y Sheikh, Jörn M Schattenberg, Zeid Kayali, Adam Zivony, Aasim Sheikh, Javier Garcia-Samaniego, Sanjaya K Satapathy, George Therapondos, Edward Mena, Detlef Schuppan, James Robinson, Jean L Chan, David T Hagerty, Arun J Sanyal. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Journal of Hepatology. 2020. DOI: 10.1016/j.jhep.2019.11.02410.1016/j.jhep.2019.11.02431887369 Search in Google Scholar